|
| 非小细胞肺癌脑膜转移诊治的研究进展 |
| Advances in Diagnosis and Treatment of Leptomeningeal Metastasis of Non-small Cell Lung Cancer |
| 投稿时间：2025-04-27 修订日期：2025-12-04 |
| DOI： |
|
 |
| 中文关键词: 脑膜转移 非小细胞肺癌 诊断 鞘内化疗 靶向治疗 免疫治疗 |
| 英文关键词:Leptomeningeal metastases Non-small cell lung cancer Diagnosis Intrathecal chemotherapy Targeted therapies Immunotherapy |
| 基金项目:国家自然科学基金项目（资助项目） |
|
| 摘要点击次数: 21 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要：脑膜转移是非小细胞肺癌（non-small cell lung cancer, NSCLC）的严重并发症，临床表现缺乏特异性，传统影像学与脑脊液细胞学检查存在一定局限性。近年来，脑脊液循环肿瘤DNA（circulating tumor DNA, ctDNA）检测技术的进展显著提升了脑膜转移的早期诊断与分子分型能力。治疗方面，目前尚未形成统一的标准化方案。针对驱动基因阳性患者，优选靶向药物及鞘内化疗，耐药后可考虑高剂量方案；对于驱动基因阴性患者，免疫治疗显示出一定的应用前景。本文综述了NSCLC脑膜转移在诊断与治疗方面的最新研究进展，为临床实践提供参考。 |
| 英文摘要: |
| Abstract: Leptomeningeal metastases represent a severe complication of non-small cell lung cancer (NSCLC), characterized by nonspecific clinical manifestations and certain limitations in traditional imaging and cerebrospinal fluid cytology examinations. In recent years, advancements in cerebrospinal fluid circulating tumor DNA (ctDNA) detection technology have significantly improved the capabilities for early diagnosis and molecular subtyping of leptomeningeal metastases. Regarding treatment, no unified standardized protocol has been established to date. For patients with driver gene positivity, targeted drugs and intrathecal chemotherapy are preferred, with high-dose regimens considered upon drug resistance; for driver gene-negative patients, immunotherapy shows promising potential. This article reviews the latest research advances in the diagnosis and treatment of leptomeningeal metastasis from non-small cell lung cancer, providing references for clinical practice. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|